Interesting, page-1812

the rest, is just a matter of allowing the inevitable to come together.
A markets growing appetite to secure their seed Apple shares.

When you put the success with low field MRI, one can draw ones own conclusions to the probability of what high field MRI 2.0 results may look like. With a significant desire, of industry to replace the toxic gadolinium contrast agent. The next movement of our collaborating partner, Siemens, you can infer for yourselves.

The great thing, is that this is many dice, MRX, MRI 2.0, New phase, Low field MRI, others, multiple path to $billions.

While we acknowledged that some absolute crap like RAP with a cough cough app were trading 125m mc, a few weeks ago, it was an obvious conclusion imo that the potential of IBX should merit the 100m mc club pre trial, ie 100-150m mc, but given the excesses of the potential here, perhaps it should be the 200m mc club pre trial, based on a a fraction of the incredible blue sky that will become ballistic with either trials yielding a fair result. Yet alone, what New phase etc, come with.

And the market will gravitate on probabilities, that at least one of our dice, if not all of them, are weighted to success given the pre clinical evidence.

Just why did 75 billion dollar Siemens approach us to collaborate? Yeah, first mover advantage, with eyes on the dinner plate.